Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.57 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692811 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL692812 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL4300160 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL3356855 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| Water SCHEMBL3030652 | 0.99 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1 | |
| Water SCHEMBL3030658 | 0.99 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1 | |
| SCHEMBL13381684 | 0.92 | — | — | |
| SCHEMBL30360356 | 0.92 | — | — | |
| SCHEMBL9583242 | 0.92 | — | — | |
| SCHEMBL30360325 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120215002-A1 | SYNTHESIS OF OPTICALLY ACTIVE INTERMEDIATE FOR THE PREPARATION OF MONTELUKAST | DSM IP ASSETS B.V. (NL) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120215002-A1 | SYNTHESIS OF OPTICALLY ACTIVE INTERMEDIATE FOR THE PREPARATION OF MONTELUKAST | ADH5, ADH1A, ADH1C | CYSLTR2 51/4885CYSLTR1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.